7:30 am Check In, Coffee & Light Breakfast
7:55 am Chair’s Opening Remarks
Designing Effective Cannabinoid Clinical Trials: Enhancing Regulatory Compliance, Patient Selection & Trial Success
8:00 am Scope Review of Clinical Trials in the Cannabinoid Drug Industry & Maintaining Momentum
Synopsis
- Analyzing clinical trials in cannabinoid therapeutics to assess their progress and prospects
- Identifying gaps in research and highlighting promising areas for future clinical investigation
- Supporting strategic planning for Phase III and IV trials to maintain momentum in cannabinoid therapeutic development
8:30 am Clinical Development Strategy for a Selective CB2 Agonist on Microglia for Alzheimer’s Disease
Synopsis
- Presentation of a selective CB2 receptor agonist acting on microglial cells to improve neuronal functions in Alzheimer’s Disease
- Overview of ongoing and planned clinical trial development focusing on inflammatory effects
- Review strategies to ensure maintenance of avoiding CB1 targeting throughout clinical development
NEW DATA
9:00 am Session Reserved for Transpharmation
9:30 am Advancing Clinical Development of SERIs for CNS Disorders
Synopsis
- Exploring the use of Selective Endocannabinoid Reuptake Inhibitors for CNS disorders
- Update on the finished Phase I clinical trial for anxiety disorder which showed positive data, brain penetration and early indications of brain effects
- Considerations and active planning to undertake phase II clinical trial later this year
NEW DATA
10:00 am Exploring the Clinical Development of the Fatty Acid Binding Protein 5 (FABP5) inhibitor ART26.12
10:30 am Speed Networking
Synopsis
This informal session provides the perfect opportunity to connect with industry pioneers and key opinion leaders in endocannabinoid and cannabinoid drug development space. Establish meaningful connections to build upon at the rest of the conference and gain exclusive first-hand insights into the latest research and developments driving progress in the space.
11:00 am Morning Break
Navigating the Political & Regulatory Landscape in Cannabinoid Drug Development to Accelerating the Path from R&D to the Clinic
11:30 am Out of the Shadow of Rimonabant? – The Re-emergence of Cannabinoid Medicines in Metabolic Dysfunction
Synopsis
• History of Cannabinoid Medicines in Metabolic Dysfunction
• Emergence of Peripherally Restricted CB1 Inverse Agonists
• Post GLP-1 / GIP Agonists – opportunities and limitations
12:00 pm Session Reserved For GB Sciences
12:30 pm Lunch
Ascertaining Patents for Cannabinoid Drugs: Overcoming Legal Barriers & Awakening Big Pharma Drive Commercialisation in the Cannabinoid Drug Development Market
1:30 pm Examining Drug Delivery Methods, Formulations & Combination Therapies Effect Patentability to Differentiate & Protect Your Products & Maximize your Return On Investment
Synopsis
- Understand how innovations in drug delivery methods and formulation design can open new avenues for securing robust, defensible patents in the cannabinoid space
- Explore how combination therapies involving cannabinoids can create unique intellectual property opportunities
- Learn strategies to tailor your patent strategy around formulation and delivery
2:10 pm Session Reserved for CitraChem
2:20 pm Roundtable Discussion: IP Strategies for Success – Navigating Patent Protection for Synthetic & Botanical Cannabinoid Therapeutics
Botanical
Synthetic
3:00 pm Afternoon Break & Scientific Poster Session
Unlocking the Full Potential of Cannabinoids: Botanical & Synthetic Strategies to Address Unmet Needs in Endometriosis
3:30 pm Advancing Botanical Cannabidiol Drugs: Insights Ffrom Endometriosis Clinical Development
Synopsis
- Exploring a strategic approach to cannabidiol drug development that prioritizes the use of naturally derived CBD isolate and the associated advantages
- Discussing the rationale for utilizing higher doses over modifications to improve bioavailability to improve drug efficacy
- Examining Ananda’s endometriosis program as a case study to highlight the clinical and regulatory strategies that enabled fast progression into human trials and why this model is important for women’s health
4:00 pm Synthetic Cannabinoid Case Study: Endometriosis
Synopsis
- Understanding the development of synthetic cannabinoids through advanced AI platforms and in silico modelling to design novel synthetic compounds
- Illustrating how these compounds bind to CB1 and CB2 receptors and how their activity can be biased
- A case study to explore the connection between the endocannabinoid system and endometriosis, emphasizing cannabinoid intervention as a promising yet under-researched therapeutic approach
NEW DATA
4:30 pm Panel Discussion: Explore How Industry Leaders are Navigating the Challenges of Bringing Cannabinoid Based Therapies to Women’s Health
Synopsis
- Explore effective strategies to engage and educate patients, clinicians, and advocacy groups to drive awareness and increase participation in cannabinoid clinical trials for endometriosis.
- Identify the key regulatory, societal, and commercial barriers limiting patient access to cannabinoid-based therapies and evaluating solutions
- Examine how industry collaboration, policy evolution, and patient advocacy can work together to accelerate the responsible adoption of cannabinoid treatments in women’s health